Related references
Note: Only part of the references are listed.Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET
Remy B. Verheijen et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Strategies to Inhibit ABCB1-and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates
Nicolas Tournier et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar
Emilia Sawicki et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2017)
Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs
Keumhan Noh et al.
ARCHIVES OF PHARMACAL RESEARCH (2017)
Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier
M. Bauer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Whole-Body Distribution and Radiation Dosimetry of 11C-Elacridar and 11C-Tariquidar in Humans
Martin Bauer et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors
Elizabeth Fox et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study
Martin Bauer et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2015)
Increased Permeability-Glycoprotein Inhibition at the Human Blood-Brain Barrier Can Be Safely Achieved by Performing PET During Peak Plasma Concentrations of Tariquidar
William C. Kreisl et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State
Deanna M. Mudie et al.
MOLECULAR PHARMACEUTICS (2014)
Bile salts enhance the intestinal absorption of lipophilic drug loaded lipid nanocarriers: Mechanism and effect in rats
Zhiwen Zhang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Interaction of 11C-Tariquidar and 11C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood-Brain Barrier
Martin Bauer et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability
Ramola Sane et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in Healthy Subjects
M. Bauer et al.
PHARMACOLOGY (2013)
Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study
Jens P. Bankstahl et al.
DRUG METABOLISM AND DISPOSITION (2013)
Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Blood-Brain Barrier: A Comparison With Rat Data
M. Bauer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier
Thomas Wanek et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2012)
The Specific P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)
Pavitra Kannan et al.
ACS CHEMICAL NEUROSCIENCE (2011)
A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
Ronan J. Kelly et al.
CLINICAL CANCER RESEARCH (2011)
The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration
I. Leitner et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET
Claudia Kuntner et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
Jame Abraham et al.
CLINICAL CANCER RESEARCH (2009)
Measurements of rat and mouse gastrointestinal pH fluid and lymphoid tissue, and implications for in-vivo experiments
Emma L. McConnell et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2008)
A regulatory viewpoint on transporter-based drug interactions
L. Zhang et al.
XENOBIOTICA (2008)
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
Christopher J. H. Porter et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Elizabeth Fox et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Ingolf Cascorbi
PHARMACOLOGY & THERAPEUTICS (2006)
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model
Xianhua Cao et al.
PHARMACEUTICAL RESEARCH (2006)
Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging
C Schiller et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes
M Wang et al.
FEMS MICROBIOLOGY ECOLOGY (2005)
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma
L Pusztai et al.
CANCER (2005)
Efflux-mediated antimicrobial resistance
K Poole
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense
EM Leslie et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2005)
Antibiotic efflux pumps in prokaryotic cells:: occurrence, impact on resistance and strategies for the future of antimicrobial therapy
F Van Bambeke et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Importance of P-glycoprotein for drug disposition in humans
MF Fromm
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2003)
Share Paper
